- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: 11F8 | IMC-11F8 | LY3012211 | Portrazza®
necitumumab is an approved drug (FDA (2015), EMA (2016))
Compound class: Antibody
Comment: Necitumumab is a monoclonal antibody with clinical antineoplastic action [1-3].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Liu M, Zhu Z. (2009)
Used in treating neoplastic diseases and hyperproliferative disorders.
Patent number: US7598350. Assignee: Imclone Llc. Priority date: 19/03/2004. Publication date: 06/10/2009.
2. Sacco PC, Maione P, Rossi A, Sgambato A, Casaluce F, Palazzolo G, Gridelli C. (2015)
Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
Expert Rev Respir Med, 9 (3): 245-54. [PMID:25797462]
3. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G et al.. (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Lancet Oncol., 16 (7): 763-74. [PMID:26045340]